Ahn, M., Kim, D., Martin, P., Davison, C., Yang, Z., Jiang, H., & Yang, J. C. (2015). BMET-37 PHASE I STUDY OF AZD3759, AN EGFR INHIBITOR WITH BLOOD BRAIN BARRIER (BBB) PENETRATION, FOR THE TREATMENT OF EGFRm+ NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASIS AND LEPTOMENGINGEAL METASTASIS. Neuro Oncol.

Ahn, Myung-Ju, Dong-Wan Kim, Paul Martin, Chris Davison, Zhenfan Yang, Haiyi Jiang, and James Chih-Hsin Yang. "BMET-37 PHASE I STUDY OF AZD3759, AN EGFR INHIBITOR WITH BLOOD BRAIN BARRIER (BBB) PENETRATION, FOR THE TREATMENT OF EGFRm+ NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASIS AND LEPTOMENGINGEAL METASTASIS." Neuro Oncol 2015.

Ahn, Myung-Ju, et al. "BMET-37 PHASE I STUDY OF AZD3759, AN EGFR INHIBITOR WITH BLOOD BRAIN BARRIER (BBB) PENETRATION, FOR THE TREATMENT OF EGFRm+ NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASIS AND LEPTOMENGINGEAL METASTASIS." Neuro Oncol 2015.